By in

Orderly Market Agreement - Director's Dealing

                                                                                                                                                                                   20 April 2018

Sativa Investments PLC

 (“Sativa” or the “Company”)

Orderly Market Agreement – Director’s Dealing

Sativa Investments PLC (NEX:SATI), the UK’s first medicinal cannabis investment vehicle, announces that, on 16 April 2018, Noel Lyons, a non-executive director of the Company, sold 750,000 ordinary shares of £0.0025 each in the Company at a price of £0.03 per share pursuant to an orderly market agreement with Peterhouse Corporate Finance Limited to satisfy market demand.

Following the sale, Noel Lyons owns 2,250,000 ordinary shares representing 0.55 per cent of the issued share capital of the Company.

The Directors of the Company accept responsibility for the contents of this announcement.

For further information please contact:

 

Geremy Thomas
Founder & CEO
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

 

NEX Exchange Corporate Adviser
Guy Miller
Peterhouse Corporate Finance Limited
+44 (0) 20 7469 0930
gm@peterhousecap.com

 

Financial PR and IR
Julian Bosdet / Dylan Mark /
Alejandra Campuzano
Abchurch Communications
+44 (0) 20 7469 4630

 

Mark Blower
Executive Director
Sativa Investments PLC
+44 (0) 20 7971 1255
enquiries@sativainvestments.co.uk

Notes to Editors

Sativa will look for well-placed opportunities within the dynamic regulatory environment of the Medicinal Cannabis sector and the Company’s investment strategy will focus on the production, testing and compliance, research and development, including pharmacology, commercialisation and sales and marketing of Medicinal Cannabis in jurisdictions where it is regulatorily accepted, with an initial focus on Canada.  The Company has committed to an independent legal review prior to each investment to verify compliance with the prevailing regulatory environment. 

The Company’s equity interest in a proposed investment may range from a minority position, to a controlling interest, or to 100 per cent ownership.  The ventures that Sativa intends to acquire can either be public or private. 

The Company’s Board and Medical Cannabis Advisory Board have a combined 60 years’ industry experience with strong and extensive contacts in the industry, with significant pharmaceutical strength and experience.  Their extensive skills range from capital fund raisings, medical research, and start-ups, to pharmaceutical development. 

For more information on Sativa Investments, please visit: https://sativainvestments.co.uk/